Kisspeptin modulates sexual and emotional brain processing in humans
Comninos AN, Wall MB, Demetriou L, Shah AJ, Clarke SA, Narayanaswamy S, Nesbitt A, Izzi-Engbeaya C, +19 more
Journal of Clinical Investigation (2017) · n=29
Kisspeptin-54 enhanced limbic-brain responses to sexual and couple-bonding stimuli and attenuated negative mood in a placebo-controlled crossover fMRI study — the first human evidence linking the hypothalamic reproductive switch to the brain's affective circuitry.
This is the Imperial College London study that opened the human kisspeptin literature beyond strictly reproductive endpoints into the affective- and reward-circuit territory the rodent work had hinted at for the better part of a decade. Investigators enrolled 29 healthy heterosexual young men (mean age 25.0 ± 0.9 years) in a double-blind, randomized, two-way crossover, placebo-controlled functional-MRI protocol. On separate study days at least seven days apart, each participant received intravenous kisspeptin-54 at 1 nmol/kg/h for 75 minutes or vehicle (gelofusine) at equivalent volume, then underwent task-based fMRI scanning while viewing visual stimuli categorized into sexual, couple-bonding, negative, and neutral conditions. Blood was sampled for kisspeptin, gonadotropin, and testosterone confirmation; mood was tracked via standardized self-report inventories.
Kisspeptin administration enhanced activity in specific limbic and paralimbic structures during sexual-image viewing — anterior and posterior cingulate cortex and left amygdala showed significant kisspeptin-versus-placebo differences. For couple-bonding stimuli the kisspeptin effect extended further into the thalamus and globus pallidus, regions previously implicated in romantic-love and pair-bonding neuroimaging studies. The brain-activity changes correlated with psychometric measures of reward, drive, mood, and sexual aversion at the individual-subject level. Kisspeptin administration also produced a measurable reduction in negative mood (p = 0.031) with no effect on positive mood. The authors framed the result as evidence that kisspeptin, beyond its established role as the principal hypothalamic gatekeeper of GnRH and the reproductive axis, integrates sexual and emotional brain processing with reproduction at the circuit level — and that the molecule plausibly carries translational interest for psychosexual disorders.
The paper is the most-cited single human study on kisspeptin's CNS effects beyond reproduction and the substantive launch point for the same group's subsequent kisspeptin-and-mood and kisspeptin-and-sexual-function trial program. Cross-link to the kisspeptin peptide page for the broader pharmacology and the Abbara et al. 2017 IVF-trigger paper for the reproductive-endpoint arm of the same group's work.
The trial population is narrow — 29 healthy heterosexual young men, all in early adulthood and recruited at a single academic-medical center. Generalizability to women, to older men, to non-heterosexual populations, and to any clinical psychosexual or affective-disorder phenotype is open and is the subject of subsequent Imperial College studies rather than this paper. The kisspeptin-54 dose is the pharmacologic-supraphysiologic infusion protocol consistent with the IVF-trigger and reproductive-endocrine studies, not a chronic-administration regimen; the fMRI findings describe acute-administration brain responses, not durable changes in limbic-circuit function. The 2025 Mills et al. J Clin Endocrinol Metab study from the same group is the load-bearing counterpoint: in a larger 95-participant crossover, biologically active kisspeptin-54 did not significantly affect prespecified anxiety endpoints in men and women, with the implication that the mood-modulation effect Comninos et al. captured may be specific to the affective-circuit response to sexual/bonding stimuli rather than a generalized anxiolytic action. The fMRI primary results are reported as cluster-corrected at standard neuroimaging thresholds; the modest sample size constrains the multiple-comparisons buffer typical of imaging studies. Industry independence is high — the trial was funded by the NIHR, MRC, and Imperial Biomedical Research Centre — and the kisspeptin-54 peptide was supplied through academic channels. No therapeutic claim for psychosexual or mood indications follows from this paper; what it establishes is the circuit-level fact that kisspeptin's effects extend beyond the hypothalamus to the limbic system in humans.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.